---
document_datetime: 2023-09-21 17:23:08
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/orgalutran-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: orgalutran-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 0.3361458
conversion_datetime: 2025-12-30 01:30:07.814436
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Procedural steps taken after granting the Marketing Authorisation

For procedures finalised after 1 May 2002 please refer to module 8B.

- The Marketing Authorisation Holder submitted to the EMEA on 29 January 2001 an application for a type I variation falling within the scope of item No. 24 (change of the method for the assay and identification of acetate in ganirelix drug substance) of Annex I to Commission Regulation (EC) No 542/95. On 7 March 2001, the EMEA approved the variation (EMEA/H/C/274/I/01). This variation did not require amendments to the Commission Decision.
- The Marketing Authorisation Holder submitted to the EMEA on 28 June 2001 an application for  one  type  I  variation  falling  within  the  scope  of  item  No  20  of  Annex  I  to  Commission Regulation (EC) No 542/95. The Marketing Authorisation Holder applied for an extension of shelf life as foreseen at the time of authorisation from 18 months to 2 years. On 16 July 2001, the EMEA approved the variation (EMEA/H/C/274/I/02). This variation required amendments to  annex  I  of  the  Community Marketing Authorisation. The respective Commission Decision was issued on 18 September 2001.
- The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  17  October  2001  an application for a type II variation in accordance with Article 6 of Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of the variation related to the update of the  Summary  of  Product  Characteristics  section  4.4  following  the  outcome  of  a  follow-up measure  concerning  the  incidence  of  congenital  malformations  after  Assisted  Reproductive Technologies (ART). On 17 January 2002, the CPMP approved the variation (EMEA/H/C/274/II/04). The respective Commission Decision was issued on 18 April 2002.